Showing results (11-20 of 80) with videos related to

Sort By:
Pageof 8
Blood|November 2, 2002
Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemiaMatthias Ritgen, Alexandra Lange, Stephan Stilgenbauer, et al.
Methods in Molecular Biology (Clifton, N.J.)|January 9, 2013
MRD detection in B-cell non-Hodgkin lymphomas using Ig gene rearrangements and chromosomal translocations as targets for real-time quantitative PCRChristiane Pott, Monika Brüggemann, Matthias Ritgen, et al.
British Journal of Haematology|November 20, 2008
Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG)Carmen D Schweighofer, Matthias Ritgen, Barbara F Eichhorst, et al.
Methods in Molecular Biology (Clifton, N.J.)|February 20, 2019
MRD Detection in B-Cell Non-Hodgkin Lymphomas Using Ig Gene Rearrangements and Chromosomal Translocations as Targets for Real-Time Quantitative PCRChristiane Pott, Monika Brüggemann, Matthias Ritgen, et al.
Haematologica|May 21, 2009
Identification of the gene encoding cyclin E1 (CCNE1) as a novel IGH translocation partner in t(14;19)(q32;q12) in diffuse large B-cell lymphomaInga Nagel, Takashi Akasaka, Wolfram Klapper, et al.
Blood|October 7, 2006
Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trialsThorsten Raff, Nicola Gökbuget, Silke Lüschen, et al.
Haematologica|April 2, 2008
Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinationsSebastian Böttcher, Matthias Ritgen, Sebastian Buske, et al.
Blood|May 27, 2006
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemiaThorsten Zenz, Matthias Ritgen, Peter Dreger, et al.
The Oncologist|July 2, 2026
Molecular Tumor Board-Guided Osimertinib Therapy in EGFR L858R/Q701L-Mutant Lung Adenocarcinoma Supported by Functional ValidationCorinna Albers-Leischner, Matthias Ritgen, Finn-Ole Paulsen, et al.
Blood|June 19, 2004
Graft-versus-leukemia activity may overcome therapeutic resistance of chronic lymphocytic leukemia with unmutated immunoglobulin variable heavy-chain gene status: implications of minimal residual disease measurement with quantitative PCRMatthias Ritgen, Stephan Stilgenbauer, Nils von Neuhoff, et al.
Pageof 8